Efficacy of a single intra-articular injection of ultra-high molecular weight hyaluronic acid for hip osteoarthritis: a randomized controlled study
- 426 Downloads
Viscosupplementation with hyaluronic acid (HA) is increasingly used for the treatment of hip osteoarthritis (OA). The purpose of this study was to compare the efficacy of intra-articular injections of an ultra-high molecular weight viscosupplement (UHMW-HA, Fermathron S) with a medium molecular weight hyaluronan (MMW-HA, Hyalubrix 60) in hip OA.
Fifty-four patients with hip OA grade 3 on the Kellgren/Lawrence scale were randomized. All infiltrations were performed under ultrasound guidance. Evaluation was performed preoperatively and at 1, 3, 6 and 12 months after infiltration. Patients were clinically evaluated using Lequesne index, VAS and WOMAC score.
Fifty patients, including 27 in the MMW-HA group and 23 in the UHMW-HA group, completed the follow-up. No significant difference was found between the two groups in terms of VAS, WOMAC or Lequesne index preoperatively or at 1, 3, 6 and 12 months after viscosupplementation. A stratified analysis was performed to study the development over time of Lequesne index of patients aged ≤ 55 years, > 55 and, ≤ 70 years and > 70 years and Lequesne index was different between the three age-stratified subgroups only in the MMW-HA group. The subgroup of older patients showed a higher Lequesne index than the subgroups of younger patients (p < 0.05).
UHMW-HA is a safe and effective treatment for hip osteoarthritis. A single dose of UHMW-HA was as effective as two doses of MMW-HA resulting in similar reductions of pain and disability.
Multicenter, independent, prospective, randomized controlled trial with level of evidence 1.
KeywordsHip osteoarthritis Regenerative medicine Hyaluronic acid Biology of cartilage Randomized clinical trial
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Human and animal participants
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
- 2.Richmond J, Hunter D, Irrgang J, Jones MH, Levy B, Marx R, Snyder-Mackler L, Watters WC 3rd, Haralson RH 3rd, Turkelson CM, Wies JL, Boyer KM, Anderson S, St Andre J, Sluka P, McGowan R, American Academy of Orthopaedic Surgeons (2009) Treatment of osteoarthritis of the knee (nonarthroplasty). J Am Acad Orthop Surg 17:591–600CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Migliore A, Tormenta S, Laganà B, Piscitelli P, Granata M, Bizzi E, Massafra U, Giovannangeli F, Maggi C, De Chiara R, Iannessi F, Sanfilippo A, Camminiti M, Pagano MG, Bagnato G, Iolascon G (2015) Safety of intra-articular hip injection of hyaluronic acid products by ultrasound guidance: an open study from ANTIAGE register. Eur Rev Med Pharmacol Sci 17:1752–1759Google Scholar
- 5.Osti L, Berardocco M, di Giacomo V, Di Bernardo G, Oliva F, Berardi AC (2015) Hyaluronic acid increases tendon derived cell viability and collagen type I expression in vitro: comparative study of four different hyaluronic acid preparations by molecular weight. BMC Musculoskelet Disord 16:284CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Vitanzo PC Jr, Sennett BJ (2006) Hyaluronans: is clinical effectiveness dependent on molecular weight? Am J Orthop (Belle Mead NJ) 35:421–428Google Scholar
- 13.Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840PubMedGoogle Scholar
- 18.Migliore A, Bella A, Bisignani M, Calderaro M, De Amicis D, Logroscino G, Mariottini F, Moreschini O, Massafra U, Bizzi E, Laganà B, Piscitelli P, Tormenta S (2012) Total hip replacement rate in a cohort of patients affected by symptomatic hip osteoarthritis following intra-articular sodium hyaluronate (MW 1500–2000 kDa) ORTOBRIX study. Clin Rheumatol 31:1187–1196CrossRefPubMedGoogle Scholar